Navigation Links
MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission

ORCHARD PARK, N.Y., Feb. 6 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) -- On February 2, 2009, the Company received a notice from NYSE Alternext US LLC (the "Exchange") stating that the Exchange intends to strike the common stock of the Company from the Exchange by filing a delisting application with the Securities and Exchange Commission pursuant to Section 1009(d) of the NYSE Alternext US Company Guide. By letter dated December 11, 2008, the Exchange had advised the Company that the Company was not in compliance with certain provision of the Exchange's Company Guide (the "Company Guide"), namely Section 1003(a)(i), with stockholders' equity of less than $2,000,000 and losses from continuing operations and net losses in two out of its three most recent fiscal years; 1003(a)(ii), with stockholders' equity of less than $4,000,000 and losses from continuing operations and net losses in three out of its four most recent fiscal years; 1003(a)(iii), with stockholders' equity of less than $6,000,000 and losses from continuing operations and net losses in its five most recent fiscal years; and 1003(a)(iv) in that it has sustained losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether it will be able to continue operations and/or meet its obligations as they mature.

By letter dated December 26, 2008 the Company notified the staff it had entered into a definitive merger agreement with Piramal Healthcare, Inc., Piramal Healthcare Limited and Mayflower Acquisition Corp. for the acquisition of the Company and requested that the Exchange continue to list the Company's stock until consummation of that merger, at which time the Company would voluntarily delist. The Exchange has advised the Company that this response did not constitute a plan of how it intends to regain compliance with the Exchanges listing standards and that therefore, there is no basis for the Exchange to provide a listing extension. It advised the Company it is therefore subject to immediate delisting proceedings. The Company intends to exercise its right to request an oral hearing to review with the Exchange its determination. There can be no assurance that the Company's request for continued listing will be granted.

About the Company

The Company is an interventional pain management company with three focus areas: (1) anesthesia and analgesia, (2) real-time image guidance, and (3) conscious sedation. The Company's products are sold throughout the world. The anesthesia and analgesia business currently manufactures and sells generic inhalation anesthetics that are used for human and veterinary surgical procedures. The Company manufactures patented real-time image guidance technologies that facilitate minimally invasive surgery. The SabreSource(TM) system and the accompanying Light Sabre(TM) disposable products have broad applications in orthopedics, neurosurgery, interventional radiology and anesthesia. They enable improved accuracy and reduced radiation in interventional procedures and support the transfer of these procedures to the outpatient setting. The Company is in the process of developing a drug/drug delivery system for the use of halogenated ethers as inhalation analgesics for conscious sedation.

Forward-Looking Statements

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, MINRAD International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of MINRAD International's Form 10-KSB/A, filed with the Securities and Exchange Commission on April 21, 2008. Although MINRAD International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

     MINRAD International, Inc.      Contact:
     50 Cobham Drive                 Charles R. Trego, Jr.
     Orchard Park, NY 14127          Executive Vice President and CFO
                                     (716) 855-1068

SOURCE MINRAD International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MINRAD International, Inc. Announces Reduction in Workforce
2. MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008
3. MINRAD International, Inc. Announces $40.0 Million Private Placement
4. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
5. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
6. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
7. AdvanDx Receives FDA 510(k) Clearance for E. coli/P. aeruginosa PNA FISH(R)
8. Dow AgroSciences Receives Approval for Cultivation of HERCULEX(R) I Corn in Brazil
9. Cell Therapeutics Receives Additional NASDAQ Notification
10. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
11. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... Creation Technologies would like to extend ... 2015 Technology Fast 500 list of the fastest growing companies in North America. ... medical device that speeds up orthodontic tooth movement by as much as 50 ...
(Date:11/24/2015)... CHARLOTTESVILLE, Va. , Nov. 24, 2015 /PRNewswire/ ... company focused on discovering drugs for metabolic disorders, ... Watkins to its Board of Directors (BOD). ... executive officer of Human Genome Sciences (HGS), and ... Industry Organization. Jim Powers , Chairman ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased to announce ... stand-alone facility will be strictly dedicated to basic USP 61, USP 62 and USP ... chance to have complete chemistry and micro testing performed by one supplier. Management ...
(Date:11/23/2015)... THOUSAND OAKS, Calif., Nov. 23, 2015   Ceres, ... company, announced today financial results for the fiscal year ... its business. --> --> ... on commercializing forage and feed products with a better ... the company signed distribution agreements with several leading crop ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):